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Abstract
Introduction: osteoporosis (OP) is a multifactorial disease which is based on a dynamic decrease in bone mass and, as 
a result, disruption of bone structure, leading to higher chances of skeletal fractures. Endothelial dysfunction is a key 
cause of impaired blood supply to the bone, resulting in a decreased perfusion, disrupted osteogenesis and, as a conse-
quence, osteoporotic changes. According to modern literature and available research, L-norvaline and rosuvastatin have 
a powerful endotheliotropic effect. However, there is no information that the osteoprotective properties of these drugs 
used as a monotherapy and as their combination have ever been studied.
Materials and Methods: Simulation of experimental osteoporosis was performed on 120 white female Wistar rats. 
After eight weeks, the operated rats developed hypoestrogenic osteoporosis. L-norvaline and rosuvastatin, both as 
a monotherapy and in their combination, were used from week 9 to week 12, inclusive. The extent of changes on 
the background of osteoporosis was estimated twelve weeks after oophorectomy. Simulation of closed osteoporotic 
fractures of the femurs and their osteosynthesis were performed on 120 white female Wistar rats. Experimental oste-
oporosis was modeled on all animals (except the control group). Eight weeks after the removal of the ovaries on the 
background of developing osteoporosis, fractures of the femur were simulated. The test drugs and their combination 
were applied from week 1 to week 4, inclusive, after the modeling of osteoporotic fractures and their osteosynthesis. 
Twelve weeks after the start of the experiment, the results of fracture consolidation were analyzed.
Results and Discussion: Rosuvastatin at a dose of 0.86 mg/kg, L-norvaline at a dose of 10 mg/kg, and their combina-
tion prevented a decrease in the level of microcirculation in the callus, had an anti-osteoporotic effect, and also contrib-
uted to an increased number of healed experimental fractures. The osteoprotective effect of the test drugs is, apparently, 
due to their endothelial-protective action.
Conclusion: The range of the pleiotropic action of drugs with endothelial-protective properties can be extended by 
adding an osteoprotective element, which, however, requires additional research.
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Introduction
Osteoporosis is a multifactorial disease which is based 
on a dynamic decrease in bone mass and, as a consequen-
ce, a disruption of bone structure, leading to higher cgan-
ces of skeletal fractures (Avrunin 1998, Benevolenskaya 
2004).
The key triggers in the development of osteoporosis 
are a decrease in calcium and vitamin D levels, a seden-
tary lifestyle, tobacco smoking, alcohol abuse, prolon-
ged intake of glucocorticoids, and rheumatoid arthritis. 
The older age, genetic determinism, weight loss and 
menopause can be attributed to the background triggers. 
The high incidence of fractures against osteoporosis pla-
ces this pathology among the main problems of modern 
public health. According to the World Health Organiza-
tion, osteoporosis is ranked fourth in the world among 
non-communicable diseases, coming after pathologies 
of the cardiovascular system, malignant neoplasms and 
diabetes. Osteoporosis has been diagnosed in 75 million 
people in Europe and Japan. 
Pharmacological drugs for the treatment of osteoporo-
sis can be divided into three groups: drugs that lower bone 
resorption (estrogens, calcitonin); drugs that stimulate 
osteogenesis (fluorides, anabolic steroids, strontium ra-
nelate); pharmacological preparations of multifactor acti-
on (vitamin D) (Lesnyak 2005, Rozhinskaya 2007). This 
division is relative, since these groups of drugs affect all 
bone formation processes. However, an increased number 
of fractures on the background of skeletal osteoporosis in-
dicates that currently there is no only way of pharmacolo-
gical treatment of this condition. This fact encourages the 
search for alternative ways of pharmacological correction 
of the pathology of bone remodeling, which determined 
the topic of this study.
Microcirculatory blood supply is essential for bone tis-
sue repair processes (Nikolova et al. 2006, Faitelson et 
al. 2010). The structure of capillary vessels in bones is 
significantly different from the structure of those in other 
tissues of the body. Their wall is composed exclusively of 
the endothelium, through which the processes of regula-
tion between the bone cells and the body are carried out 
(Gudyrev et al. 2011).
Endothelial dysfunction is a key cause of impaired 
blood supply to the bone, resulting in impaired perfusion, 
impaired osteogenesis and, as a result, osteoporotic chan-
ges (Kloen et al. 2003). 
Previously conducted experimental studies proved sig-
nificant osteoprotective effects of substances that minimi-
ze endothelial dysfunction, such as angiotensin-conver-
ting-enzyme (ACE) inhibitor enalapril, angiotensin (AT) 
receptor blocker losartan and phytoalexin resveratrol 
(Faitelson et al. 2010, Gudyrev et al. 2011, Kloen et al. 
2003).
According to modern literature and available rese-
arch, L-norvaline and rosuvastatin have a powerful en-
dotheliotropic effect (Coffin et al. 1995, Molchanova 
2016). However, there is no information that the osteo-
protective properties of these drugs used as a monothe-
rapy and as their combination have ever been studied.
Objective of the study
To assess the osteoprotective activity of L-norvaline, 
rosuvastatin and their combination in comparison with 
Bivalos® (strontium ranelate) when correcting experi-
mental osteoporosis and fractures related to it ,caused by 
bilateral ovariectomy.
Materials and research methods
The conduct of this study was approved by the local 
ethical committee for working with laboratory animals. 
Experimental osteoporosis was simulated on 120 white 
female Wistar rats weighing from 200 to 300g. To si-
mulate experimental osteoporosis, the rats were anes-
thetized by intraperitoneal administration of a 300 mg/
kg aqueous solution of chloral hydrate, after which an 
operation – bilateral ovariectomy – was performed. Af-
ter eight weeks, the operated rats hypoestrogenic deve-
loped osteoporosis (Stabrovskaya 2011, Faitelson et al. 
2010). The test pharmacological preparations, both as a 
monotherapy and as their combination, were used from 
week 9 to week 12, inclusive. For the purpose of control, 
a group of rats was formed, in which the animals under-
went anesthesia for an abdominal opening, without ha-
ving the ovaries removed and with layered wound closu-
re (false ovariectomy).
The extent of the changes on the background of oste-
oporosis was assessed twelve weeks after ovariectomy by 
histomorphometry.
Modeling of closed osteoporotic fractures of the femo-
ral bones and their osteosynthesis were performed on 120 
white female Wistar rats with a body weight from 200 to 
300g. In all the animals (except the control group), expe-
rimental osteoporosis was simulated. After eight weeks, 
in the operated rats developed systemic osteoporosis.
Eight weeks after the removal of the ovaries against the 
background of developing osteoporosis, femoral fractures 
were modeled (osteoporotic fractures).
In order to simulate experimental osteoporotic fractu-
res, an external impact was applied to the metaphysis with 
a load perpendicular to the bone axis, until a transverse, 
oblique, or comminuted fracture appeared in it (Certifica-
te for rationalization proposal No. 1975-11 11.23.11). In 
order to stabilize the fracture zone, a minimally invasive, 
closed intramedullary pin osteosynthesis was performed. 
Absence of pathological mobility in the fracture zone 
served as a criterion for the adequacy of osteosynthe-
sis (Certificate for rationalization proposal No. 1974-11 
11.23.11).
The test drugs and their combination were applied 
from week 1 to week 4, inclusive, after modeling os-
teoporotic fractures and their osteosynthesis. Twelve 
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weeks after the start of the experiment, the results of 
fracture consolidation were analyzed macroscopically 
and radiographically.
Measurement of microcirculation in the bone tissue 
was assessed in the proximal metaphyseal part of the fe-
mur, and in the case of modeling osteoporotic fractures – 
in the early callus. For this, the rats were anesthetized by 
intraperitoneal injection of an aqueous solution of chloral 
hydrate at a dose of 300 mg/kg; then an operative access 
was achieved to the proximal metaphyseal region of the 
femur. In the cortical bone layer or on the surface of the 
callus, a perforation hole was being formed, into which a 
needle sensor was inserted to determine a level of local 
microcirculation.
Bone perfusion was investigated on equipment manu-
factured by Biopac Systems: MP100/150 polygraph and 
Laser Doppler Flowmetry module (LDF) LDF100C with 
an invasive needle-shaped TSD144 sensor for inserting 
into the proximal metaphyseal part of the femur.
At the time of the study of experimental osteoporosis, 
after measuring the level of bone perfusion, without chan-
ging the position of the sensor, vascular tests were per-
formed for endothelium-dependent vasodilation (EDVD) 
(response to a bolus intravenous administration of a solu-
tion of acetylcholine at a dose of 40 μg/kg) and endothe-
lium-nondependent vasodilatation (ENVD) (intravenous 
administration of a solution of sodium nitroprusside at a 
dose of 30 µg/kg) in order to calculate the coefficient of 
endothelial dysfunction (CED) and to assess the severity 
of endothelial dysfunction.
The registration and processing of the results of Laser 
Doppler Flowmetry with functional vascular sampling 
was performed using AcqKnowledge software versions 
3.8.1-4.2.0. Microcirculation values are expressed in per-
fusion units (PU).
To assess changes in bone tissue against the back-
ground of experimental osteoporosis and its pharma-
cotherapy with the test drugs and their combinations, a 
histological examination of bone tissue in the proximal 
metaphysis of the femur was performed.
After the animals were removed from the experiment, 
hematoxylin-eosin (HE) stained histological specimens 
were made from their femurs. The histological preparati-
ons were studied using light microscopy (Leica CME mi-
croscope, magnification x100: objective lens x10, eyepie-
ce x10) with photofixation.
To study bone microarchitecture, the previously ca-
librated ImageJ software, versions 1.39-1.43, was used. 
The width of the bone trabeculae, expressed in microme-
ters, was used as a quantitative measure to assess the de-
velopment of osteoporosis and the effecacy of its medical 
correction.
All the animals were divided into groups through stra-
tified randomization according to their body weight, hus-
bandry and nutrition conditions, as well as to operations 
and manipulations performed. During the experiment, the 
animals were kept in a standard experimental biologically 
clean room, the air temperature was 22-2)° C, illuminati-
on – the light/dark cycle (12 h/12 h), all the rats received 
granulated feed and filtered water.
In this paper, all the experimental data obtained were 
analyzed using descriptive statistics (Microsoft Excel 
analysis package). For group indicators, mean values (M) 
and error of mean (m) were determined, data in the text 
and tables are presented as M±m. The analysis of statis-
tically significant differences in intergroup comparisons 
was performed by the heteroscedastic t-test. When ana-
lysing a large number of comparisons, a Student-New-
man-Keuls test was used.
Results and Discussion
In accordance with the design of the experiment, eight 
weeks after the operation of bilateral ovariectomy in fe-
male Wistar rats, therapy was started with a reference 
drug, strontium ranelate (Bivalos) at a dose of 171 mg/
kg. This animals received this preparation in a 1% starch 
solution once a day intragastrically for four weeks. Biva-
los is the most common and frequently prescribed drug 
for the prevention and pharmacological correction of os-
teoporosis.
Based on the data obtained, it was found that the cho-
sen drug had no effect on the average level of bone per-
fusion in the proximal metaphyseal zone of the rat femur.
The LDF values in the group of animals treated with 
Bivalos were statistically significantly different from tho-
se in the group of sham-operated animals, but were not 
statistically significantly different from those in the group 
of rats with osteoporosis.
Determination of the coefficient of endothelial dys-
function in the rats treated with Bivalos made it possible 
to confirm that this drug had no endotheliotropic activity.
Microscopic examination of the sections in the stu-
died site of the rats treated with Bivalos pharmacothera-
py revealed the absence of microfractures of trabeculae, 
clearer contours of the bone trabecular network and wider 
bone trabeculae than in the animals with an osteoporosis 
model.
In the group of the rats treated with the test drug, it was 
found and confirmed that there was a direct relationship 
between the level of microcirculation in the bone tissue of 
the proximal femur metaphysis and the average width of 
the bone trabeculae in the studied site. The data obtained 
are shown in Table 1.
In accordance with the experimental protocol, eight 
weeks after the operation of bilateral oophorectomy, the 
female rats were administered rosuvastastin at a dose of 
0.86 mg/kg intragastrically once a day in form of a sus-
pension in 1% starch solution for four weeks.
After 12 weeks, the group of animals to which this 
drug was injected, the indicators of bone perfusion in the 
cancellous bone tissue of the proximal part of the right 
femur were recorded. Rosuvastatin at the studied dosage 
was found to prevent a decrease in the level of regional 
microcirculatory blood flow in the studied area, keeping 
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it at the level of the control rats – 81.88±3.39 PU. Rosu-
vastatin at a dose of 0.86 mg/kg increased by 39.4% the 
level of regional microcirculation in the bone tissue of the 
proximal femur, compared with the parameters in the ani-
mals with a model of hypoestrogenic osteoporosis.
Microscopy data from the proximal metaphyseal fe-
murs of the animals that had received rosuvastatin phar-
macotherapy showed a preserved microarchitecture and 
wider bone trabeculae than in the rats with experimental 
osteoporosis. The value of the average width of the bone 
trabeculae exceeded by 16.6% the same indicator in the 
untreated rats with an osteoporosis model and amounted 
to 75.31±0.97 μm (Table 2).
In accordance with the study protocol, L-norvaline at a 
dose of 10 mg/kg was administered intragastrically daily 
as a suspension in 1% starch solution for four weeks, 
eight weeks after bilateral oophorectomy.
After 12 weeks, the microcirculation indicators in 
the cancellous bone of the proximal right femur were 
recorded. It was established that L-norvaline at the stu-
died dosage prevented a decrease in the level of regional 
microcirculation in the studied area while maintaining 
the parameters of bone perfusion at the level of the con-
trol group of animals – 92.46±2.29 PU. Thus, it was re-
liably established that L-norvaline at a dose of 10 mg/
kg increased the level of microcirculation in the bone 
tissue of the studied site by 52.4% compared with the 
indicators in the animals with a model of hypoestrogenic 
osteoporosis. 
The functional vascular test for EDVD and ENVD 
and the calculation of the coefficient of endothelial dys-
function in the animals treated with L-norvaline against 
the background of osteoporosis showed that L-norvaline 
brought CED values closer to the values of the control 
group of animals, reducing it to 1.64±0.21.
A morphometric study found that L-norvaline in the 
studied dosage prevented a decrease in the average width 
of bone trabeculae to the level of the animals with expe-
rimental osteoporosis. However, the average width of tra-
beculae did not reach the values of the control rats. This 
indicator was 81.24±0.68 μm, which was 25.7% higher 
than that in the rats with an osteoporosis model. Thus, 
twelve weeks after modeling osteoporosis in the rats, 
L-norvaline at a dose of 10 mg/kg had an osteoprotective 
effect of improving bone microarchitecture and preven-
ting the thinning of bone trabecula (Table 3).
According to the experimental protocol, eight weeks 
after the operation of bilateral ovariectomy, the female 
rats were administered rosuvastatin at a dose of 0.86 mg/
kg and L-norvaline at a dose of 10 mg/kg intragastrically 
once a day in form of a suspension of 1% starch solution 
for four weeks.
An assessment of intraosseous microcirculation in the 
trochanteric region of the femur showed that rosuvastatin 
in combination with L-norvaline (at the studied dosages) 
increased the level of bone perfusion of the proximal fe-
mur metaphysis against the background of experimental 
osteoporosis. The average value of the microcirculation 
Table 2. Dynamics of Indicators of Microcirculation, CED and the Width of the Bbone Trabeculae on the Model of Experimental 
Osteoporosis and Its Correction with Rosuvastatin at a dose of 0.86 mg/kg compared with Bivalos
Group of animals Microcirculation value, (PU) CED Width of the bone trabeculae, (μm)
Control
(n=20) 99.91±3.41 1.28±0.18 96.64±1.01
Osteoporosis
(n=20) 58.75±3.76* 2.57±0.23* 64.61±0.54*
OP+Bivalos
(n=20) 67.48±2.98 2.44±0.19 80.19±0.95**
OP+ Rosuvastatin
(n=20) 81.88±3.39** 1.72±0.18** 75.31±0.97**
Note:  * – p<0.05 compared to control; ** – p<0.05 compared to the pathology group
Table 1. Dynamics of Indicators of Microcirculation, CED and the Width of Bone Trabeculae on the Model of Experimental Oste-
oporosis and Its Correction with Bivalos at a Dose of 171 mg/kg
Group of animals Microcirculation value, (PU) CED Width of the bone trabeculae, (μm)
Control
(n=20) 99.91±3.41 1.28±0.18 96.64±1.01
Osteoporosis
(n=20) 58.75±3.76* 2.57±0.23* 64.61±0.54*
OP+Bivalos
(n=20) 67.48±2.98 2.44±0.19 80.19±0.95**
Note: * – p<0.05 compared to control; ** – p<0.05 compared to the pathology group
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level was 88.02±3.03 PU, which was 49.8% higher than 
in the animals with experimental osteoporosis without 
pharmacological correction. 
After measuring the values of intraosseous perfu-
sion, the coefficient of endothelial dysfunction was 
calculated. It was found that the combination of rosu-
vastatin and L-norvaline approximated the proportions 
between the areas of the triangles above the recovery 
curves of the bone microcirculation level when perfor-
ming functional vascular tests to such in the control ani-
mals. Thus, the combination therapy with rosuvastatin 
and L-norvaline statistically significantly reduced CED 
to the values of 1.68±0.25. The indicators of CED in 
the combination pharmacotherapy with the test drugs 
were statistically significantly different from those in 
the group of animals with osteoporosis without treat-
ment, as well as in the rats receiving the reference drug 
Bivalos (p<0.05).
Rosuvastatin at a dose of 0.86 mg/kg in combination 
with L-norvaline at a dose of 10 mg/kg prevented a de-
crease in the average width of bone trabeculae to the level 
of the animals with experimental osteoporosis. However, 
the average width of the trabeculae did not reach the va-
lues obtained in the sham-operated rats. This indicator 
was 30% higher than in the animals with osteoporosis 
without ongoing treatment, and amounted to 84.02±0.89 
μm (Table 4). 
According to the design of the experiment, eight weeks 
after bilateral removal of the ovaries in the female rats, 
osteoporotic fractures of the right femur were simulated 
followed by its osteosynthesis. 
According to the study protocol, eight weeks after the 
removal of the ovaries, two groups of rats were formed 
in order to simulate an osteoporotic fracture of the femur 
and its subsequent osteosynthesis, as well as the start of 
monotherapy with the test L-norvaline at a dose of 10 mg/
kg and the reference drug Bivalos at a dose of 171 mg/kg 
These drugs were administered daily intragastrically for 
four weeks after modeling a fracture of the proximal fe-
mur metaphysis with its subsequent osteosynthesis. Four 
weeks later, the level of bone perfusion in the callus of 
the consolidated fracture, a visual and radiological ana-
lysis of the quality and number of bone healings, as well 
as morphometric determination of the width of the bone 
trabeculae were performed.
L-norvaline at a dose of 10 mg/kg had a positive effect 
on the microcirculation indicators in the conditions of ex-
perimental osteoporotic fractures of the proximal femur 
Table 3. Dynamics of Indicators of Microcirculation, CED and the Width of Bone Trabeculae on the Model of Experimental Oste-
oporosis and Its Correction with L-norvaline at a Dose of 10 mg/kg Compared with Bivalos
Group of animals Microcirculation value, (PU) CED Width of the bone trabeculae, (μm)
Control
(n=20) 99.91±3.41 1.28±0.18 96.64±1.01
Osteoporosis
(n=20) 58.75±3.76* 2.57±0.23* 64.61±0.54*
OP+Bivalos
(n=20) 67.48±2.98 2.44±0.19 80.19±0.95**
OP+ 
L-norvaline (n=20) 92.46±2.29** 1.64±0.21** 81.24±0.68**
Note:  * – p<0.05 compared to control; ** – p<0.05 compared to the pathology group
Table 4. Dynamics of Indicators of Microcirculation, CED and the Width of Bone Trabeculae on the Model of Experimental Os-
teoporosis and Its Correction with a Combination of L-norvaline at a Dose of 10 mg/kg and Rosuvastatin at a Dose of 0.86 mg/kg 
Compared with Bivalos
Group of animals Microcirculation value, (PU) CED Width of the bone trabeculae, (μm)
Control
(n=20) 99.91±3.41 1.28±0.18 96.64±1.01
Osteoporosis
(n=20) 58.75±3.76* 2.57±0.23* 64.61±0.54*
OP+Bivalos
(n=20) 67.48±2.98 2.44±0.19 80.19±0.95**
OP+ 
L- norvaline + Rosu-
vastatin
(n=20)
88.02±3.03** 1.68±0.25** 84.02±0.89**
Note:  * – p<0.05 compared to control; ** – p<0.05 compared to the pathology group
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metaphysis, unlike the reference drug Bivalos, which did 
not have such an effect.
In the animals treated with L-norvaline at a dose of 10 
mg/kg, the average width of bone trabeculae was higher 
compared to the animals with osteoporotic femoral frac-
tures (not receiving pharmacotherapy) which had recei-
ved Bivalos, and exceeded the similar indicator in the rats 
with femoral fractures without osteoporosis.
An X-ray and visual evaluation of the results of oste-
oporotic fracture healing revealed that, against the back-
ground of administering Bivalos and L-norvaline to the 
rats for four weeks after modeling and osteosynthesis of 
osteoporotic fractures,, there were no unsatisfactory re-
sults – consolidation of osteoporotic fractures was obser-
ved in 100% of cases.
According to the experimental design, a group of rats 
received a daily monotherapy with rosuvastatin at a dose 
of 0.86 mg/kg for four weeks after modeling and oste-
osynthesis of experimental osteoporotic fractures of the 
proximal metaphyseal part of the femur.
Rosuvastatin at a dose of 0.86 mg/kg positively in-
fluenced the level of bone perfusion in the callus of ex-
perimental fractures of the proximal metaphyseal region 
of the femur compared with the animals treated with Bi-
valos.
In addition, the microcirculation value in the group 
of animals treated with a rosuvastatin monotherapy was 
higher than that in the group of control animals with expe-
rimental fractures without osteoporosis, but it was slightly 
lower than the microcirculation values in the group of the 
rats treated with L-norvaline.
In the animals treated with a rosuvastatin monothera-
py at a dose of 0.86 mg/kg, the average width of bone 
trabeculae was higher than in the group of animals with 
fractures due to osteoporosis and receiving a reference 
drug Bivalos, but did not exceed such in the animals from 
the control group. It can be noted that the width of bone 
trabeculae in the group of rats treated with a rosuvastatin 
monotherapy was slightly lower than in the animals trea-
ted with a L-norvaline monotherapy.
The visual and X-ray monitoring of the results of 
consolidation of experimental osteoporotic fractures 
showed that, with a rosuvastatin monotherapy at a dose 
of 0.86 mg/kg for four weeks after modeling and os-
teosynthesis of experimental osteoporotic fractures, 
no unsatisfactory bone healing results were observed: 
consolidation of osteoporotic fractures was recorded in 
100% of cases.
The design of the experiment also provided for the for-
mation of a group of rats receiving combined L-norvaline 
pharmacotherapy at a dose of 10 mg/kg and rosuvastatin 
at a dose of 0.86 mg/kg for four weeks from the moment 
of modeling and osteosynthesis of osteoporotic fractures 
of the proximal metaphysis of the femur.
The combined pharmacotherapy with rosuvastatin at a 
dose of 0.86 mg/kg and L-norvaline at a dose of 10 mg/
kg had a positive effect on the level of perfusion in an in-
terfragmental callus of osteoporotic fractures of the proxi-
mal femur metaphysis, compared with the animals treated 
with Bivalos.
In the animals treated with a combination pharma-
cotherapy with L-norvaline at a dose of 10 mg/kg and 
rosuvastatin at a dose of 0.86 mg/kg, the average width 
of bone trabeculae was higher than in the group of rats 
without pharmacotherapy, and also in the group treated 
with Bivalos, and was as close as possible to a similar 
indicator in the rats with femoral fractures without oste-
oporosis. The width of bone trabeculae on the background 
of the combined pharmacotherapy was higher than that in 
the animals treated with L-norvaline and rosuvastatin as 
a monotherapy.
A visual and X-ray evaluation of the results of consoli-
dation of experimental osteoporotic fractures showed that 
the combination pharmacotherapy with rosuvastatin at a 
dose of 0.86 mg/kg and L-norvaline at a dose of 10 mg/
kg for four weeks after modeling and osteosynthesis of 
experimental osteoporotic fractures had no unsatisfactory 
bone healing results: consolidation of osteoporotic frac-
tures was observed in 100% of cases. The results of this 
experimental study are shown in Table 5.
Table 5. Dynamics of Indicators of Microcirculation, Width of Bone Trabeculae and the Number of Healed Fractures on the Model 
of Experimental Osteoporotic Fractures and Their Correction with L-norvaline at a Dose of 10 mg/kg, Rosuvastatin at a Dose of 
0.86 mg/kg, and Their Combination Compared to Bivalos
Group
Indicators under study
Microcirculation 
value, (PU)
Width of the bone 
trabeculae, (μm)
Number of healed 
fractures
Number of unhealed 
fractures
Control 89.30±4.75 92.93±1.57 15 5
Osteoporosis 66.59±3.61* 59.13±1.65* 11 9
Bivalos 70.39±2.39 79.16±1.43** 20 0
Rosuvastatin 94.34±2.54** 84.13±1.24** 20 0
L-norvaline 107.14±3.37** 86.25±1.31** 20 0
Rosuvastatin + L-norvaline 104.01±3.90** 90.43±1.48** 20 0
Note:  * – p<0.05 compared to control; ** – p<0.05 compared to the pathology group
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Conclusion
The proper microcirculatory bed and its condition are a 
key condition for maintaining bone homeostasis. The de-
terioration of the blood supply to the bone tissue leads 
to the development of such pathological conditions of 
the musculoskeletal system as: osteonecrosis, osteomye-
litis (Curban et al. 1993) and osteoporosis (Coffin et al. 
1995). The processes of neoangiogenesis and the normal 
blood supply to the bone fragments in the osteoreparation 
process play a key role. A trauma to the musculoskeletal 
system leads to inevitable damage to the supply vascular 
network and, consequently, to tissue hypoxia, which cau-
ses poor fracture consolidation (Kloen et al. 2003).
The vascular endothelium performs the main regu-
latory function, provides a link with other layers of the 
vascular wall, responding to their needs by isolating me-
diators (Madeddu 2005). Thus, the endothelial layer of 
blood vessels in the bone tissue is an integral part of the 
bone and is responsible for the level of regional microcir-
culation.
This fact has been confirmed by a number of studies 
claiming, for example, that VEGF (the key regulator of 
the cascade of events leading to the formation and de-
velopment of the vascular system) plays a key role in 
the remodeling and repair of bone damage (Gerstenfeld 
et al. 2003). Inhibition of VEGF leads to an increase in 
the width of the tibial and femoral growth zones (Fai-
telson et al. 2010), slower angiogenesis processes in the 
growth plates, depletion of the vascular network of the 
metaphyseal zone, as well as deterioration of the forma-
tion of trabecular bone structure and resorption of can-
cellous bone tissue (Meury et al. 2006). Inhibition of 
VEGF against the background of a femoral fracture in 
mice leads to a decrease in blood vessel invasion, callus 
mineralization and impaired bone trabeculae remodeling 
(Gerstenfeld et al. 2003; Meury et al. 2006). Stimulation 
of the endosteal circulation in the damaged bone, with 
skeletal bone fractures (Nikolova and Strilic 2006) al-
lows mesenchymal cells to penetrate into the damaged 
area (Madeddu 2005) and differentiate themselves into 
osteoblastic cells with the subsequent formation of can-
cellous bone.
The processes of remodeling and reparative regenera-
tion of bone tissue are directly dependent on the quality 
of functioning of the vascular endothelium, the purpose of 
which is to regulate the level of regional microcirculation 
in bone tissue.
Endothelial dysfunction – an imbalance of opposite-
ly acting processes: vasorelaxing and vasoconstricting, 
procoagulant and anticoagulant, growth factors and their 
inhibitors – is the cause of disorders of the blood supply 
to the bone tissue, and, therefore, disorders of remodeling 
and repair of bone damage.
The drugs with endothelioprotective properties are 
currently being actively srudied. So far, there are no me-
ans for the specific correction of endothelial dysfunction, 
and therefore the search is under way in various groups 
of drugs. The representatives of statins – rosuvastatin and 
arginase inhibitor L-norvaline – as well as their combined 
use – seem to be the most worthwhile.
One of the possible mechanisms of the endotheliopro-
tective effect of rosuvastatin, L-norvaline and their com-
bination is an increase in production and accumulation 
of NO.
Thus, rosuvastatin and L-norvaline, and their combi-
nation, have an endothelioprotective effect on the bone 
tissue vessels, effectively prevent a decrease in the regio-
nal blood flow in the bone tissue against the background 
of osteoporosis and experimental osteoporotic fractures, 
and, therefore, have an osteoprotective effect, consisting 
in the positive influence of the test drugs on bone remode-
ling and osteoreparation processes.
The range of the pleiotropic action of drugs with endo-
thelial-protective properties can be extended by adding an 
osteoprotective element, which, however, requires additi-
onal research.
Findings
1. On the model of osteoporosis caused by bilateral oo-
phorectomy, it was established that L-norvaline at a 
dose of 10 mg/kg had an endothelium protective ef-
fect, reducing the coefficient of endothelial dysfunc-
tion to 1.64±0.21, prevents a decrease in blood flow 
indicators in the femoral bone tissue (92.46±2.29 PU), 
and also increases the width of the bone trabeculae to 
81.24±0.68 μm and prevents trabecula microfractures, 
proving its osteoprotective effect.
2. On the model of osteoporosis caused by bilateral oo-
phorectomy, it was established that rosuvastatin at a 
dose of 0.86 mg/kg had an endothelioprotective effect, 
reducing the coefficient of endothelial dysfunction to 
1.72±0.18, prevents a decrease in blood flow indica-
tors in the femoral bone tissue (81.88±3.39 PU), and 
also increases the width of the bone trabeculae to 
75.31±0.97 μm and prevents trabecula microfractures, 
proving its osteoprotective effect.
3. On the model of osteoporosis caused by bilateral oo-
phorectomy, it was established that the combined use 
of L-norvaline at a dose of 10 mg/kg and rosuvastatin 
at a dose of 0.86 mg/kg had an endothelium protective 
effect, reducing the endothelial dysfunction coefficient 
to 1.68±0.25, preventing a decrease indicators of blood 
flow in the bone tissue of the femur (88.02±3.03 PU), 
and also increases the width of the bone trabeculae to 
84.02±0.89 μm and prevents trabecula microfractures, 
proving its osteoprotective effect.
4. On the model of experimental osteoporotic fractures, 
it was established that L-norvaline at a dose of 10 mg/
kg increased the microcirculation indicators in the 
fracture zone of the proximal femoral metaphysis to 
107.14±3.37 PU, increases the width of bone trabecu-
lae to 86.25±1.31 μm and contributes (in 100% of cas-
es) to the consolidation of fractures, thereby proving its 
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osteoprotective effect.
5. On the model of experimental osteoporotic fractures, it 
was established that rosuvastatin at a dose of 0.86 mg/
kg increases the microcirculation indicators in the zone 
of fracture of the proximal metaphysis of the femur to 
94.34±2.54 PU, increases the width of bone trabeculae 
to 84.13±1.24 μm and contributes (in 100% of cases) 
to the consolidation of fractures, thereby proving its 
osteoprotective effect.
6. On the model of experimental osteoporotic fractures, 
it was found that the combination of L-norvaline at a 
dose of 10 mg/kg and rosuvastatin at a dose of 0.86 
mg/kg increases the microcirculation indicators in the 
zone of fracture of the proximal femoral metaphysis to 
104.01±3.90 PU, increases the width of bone trabecu-
lae up to 90.43±1.48 μm and contributes (in 100% of 
cases) to the consolidation of fractures, thereby prov-
ing its osteoprotective effect. 
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